CentroDerm GmbH

Wuppertal 9 trials 5 recruiting

9 Registered trials

5 Currently recruiting

Organisation

CentroDerm GmbH

Location

Wuppertal, Germany

Identifier

ORG-100041212

Address

Heinz-Fangman-Strasse 57, Barmen, 42287, Germany

Departments

-
Centroderm GmbH
Dermatology
N/A
Studienzentrum

Clinical trials at this site (9)

Search interface

A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated all… Recruiting

2025-524580-21-00 Grass pollen induced allergic rhinitis or rhinoconjunct 10 2026-06-01
Clinical trial of VDA-1102 ointment for patients with actinic keratosis Recruiting

2025-522482-30-00 Actinic keratosis 4 2026-02-11
A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo… Recruiting

2025-520499-24-00 Moderate to Severe Platysma Prominence 5 2025-10-01
5% KOH solution vs placebo treatment of actinic keratosis with different treatment duration Recruiting

2024-514277-21-00 Actinic keratosis 5 2025-03-19
Evaluation of the efficacy and safety of a new gel containing 10 mg/g Clindamycin and 0.25 mg/g Tretinoin vs. the originator Acnatac(R) 10 m… Recruiting

2023-504552-10-01 Papulopustular acne 5 2024-05-14
A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered sub… Ended

2024-515717-17-00 birch pollen-induced allergic rhinitis birch pollen-ind 5 2024-10-28
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety deucravacitinib in patients with chronic hand eczem… Ended

2023-504298-19-00 Chronic Hand Eczema 4 2024-07-18
A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibul… Ended

2023-505487-11-00 Actinic Keratosis on the Face or Scalp 5 2023-12-21
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended

2022-502361-15-00 Moderate-to-Severe Plaque Psoriasis 5 2019-12-12